BrainEver Secures $33M to Accelerate Revolutionary Neurodegeneration Therapies

BrainEver is thrilled to announce that we have secured $33,000,000 in our latest funding round, marking a significant milestone in our journey to revolutionize the treatment of age-related neurodegenerative diseases. As a pioneering biopharmaceutical company, BrainEver is dedicated to developing a new generation of therapies aimed at halting disease progression and restoring neuronal function. Our focus on recombinant human Homeoproteins (HPs) stems from our commitment to preventing neuronal loss and rejuvenating the overall physiology and metabolism of affected neurons. This innovative approach is deeply rooted in the groundbreaking research conducted by our co-founder Alain Prochiantz and his team, and further bolstered by the strategic vision of co-founder Bernard Gilly. The newly raised capital will fuel the advancement and clinical development of our lead project, BREN02, which focuses on recombinant human Engrailed-1 (hEN1) as a promising treatment for patients with Amyotrophic Lateral Sclerosis (ALS). This investment not only supports the progression of BREN02 towards critical clinical trials, slated for launch by 2025, but also underpins our broader mission to address diseases such as Charcot disease, Parkinson’s, and glaucoma—the second leading cause of blindness. With this robust financial backing, BrainEver is poised to accelerate its research and development pipeline, bringing hope and transformative therapies to countless patients grappling with debilitating neurodegenerative conditions. We are excited for what lies ahead and remain committed to our vision of making lasting, positive impacts on patients’ lives through cutting-edge scientific innovation. Follow us on this remarkable journey as we continue to push the boundaries of biopharmaceutical research and therapeutic development.